MX2018002223A - Derivados de insulina novedosos y usos medicos de los mismos. - Google Patents

Derivados de insulina novedosos y usos medicos de los mismos.

Info

Publication number
MX2018002223A
MX2018002223A MX2018002223A MX2018002223A MX2018002223A MX 2018002223 A MX2018002223 A MX 2018002223A MX 2018002223 A MX2018002223 A MX 2018002223A MX 2018002223 A MX2018002223 A MX 2018002223A MX 2018002223 A MX2018002223 A MX 2018002223A
Authority
MX
Mexico
Prior art keywords
insulin derivatives
medical uses
derivatives
novel insulin
uses hereof
Prior art date
Application number
MX2018002223A
Other languages
English (en)
Inventor
Madsen Peter
HOSTRUP Susanne
Münzel Martin
Ulrich Hjørringgaard Claudia
Fledelius Christian
Murray Anthony
Glendorf Tine
Norrman Mathias
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2018002223A publication Critical patent/MX2018002223A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)

Abstract

La presente invención se relaciona con los campos terapéuticos de medicamentos para condiciones médicas relacionadas con diabetes. De manera más específica, la invención se relaciona con derivados acilados novedosos de análogos de insulina humana. La invención también proporciona composiciones farmacéuticas que comprenden a estos derivados de insulina y se relaciona con el uso de estos derivados para el tratamiento o prevención de condiciones médicas relacionadas con diabetes.
MX2018002223A 2015-08-25 2016-08-24 Derivados de insulina novedosos y usos medicos de los mismos. MX2018002223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15182282 2015-08-25
PCT/EP2016/069972 WO2017032798A1 (en) 2015-08-25 2016-08-24 Novel insulin derivatives and the medical uses hereof

Publications (1)

Publication Number Publication Date
MX2018002223A true MX2018002223A (es) 2018-03-23

Family

ID=54007591

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002223A MX2018002223A (es) 2015-08-25 2016-08-24 Derivados de insulina novedosos y usos medicos de los mismos.

Country Status (15)

Country Link
US (1) US11352406B2 (es)
EP (1) EP3341403B1 (es)
JP (2) JP2018531900A (es)
KR (1) KR20180038049A (es)
CN (1) CN108026157B (es)
AR (1) AR106364A1 (es)
AU (1) AU2016311283B2 (es)
BR (1) BR112018002416A2 (es)
CA (1) CA2996455A1 (es)
ES (1) ES2908373T3 (es)
IL (1) IL257173A (es)
MX (1) MX2018002223A (es)
RU (1) RU2018107727A (es)
TW (1) TW201717998A (es)
WO (1) WO2017032798A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016311283B2 (en) 2015-08-25 2020-10-08 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3668892A1 (en) 2017-08-17 2020-06-24 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
CN112789289A (zh) 2018-10-05 2021-05-11 诺和诺德股份有限公司 包含胰岛素肽和egf(a)肽的双功能化合物
KR102507156B1 (ko) 2019-03-29 2023-03-09 노보 노르디스크 에이/에스 포도당 민감성 인슐린 유도체
KR20220112817A (ko) 2019-12-10 2022-08-11 사노피 설폰아미드 및 폴리펩티드의 콘주게이트를 형성하는 방법
EP4073097A1 (en) * 2019-12-11 2022-10-19 Novo Nordisk A/S Novel insulin analogues and uses thereof
KR20220121833A (ko) * 2019-12-30 2022-09-01 간 앤 리 파마슈티칼스 컴퍼니, 리미티드 인슐린 유도체
EP4347632A1 (en) * 2021-05-24 2024-04-10 Sunshine Lake Pharma Co., Ltd. A novel acylated insulin analog

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK105489D0 (da) 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
AU641721B2 (en) * 1989-12-21 1993-09-30 Novo Nordisk A/S Insulin preparations containing nicotinic acid or nicotinamide
JP3014764B2 (ja) 1993-09-17 2000-02-28 ノボ ノルディスク アクティーゼルスカブ アシル化インスリン
ZA954983B (en) 1994-06-17 1996-02-14 Novo Nordisk As N-terminally extended proteins expressed in yeast
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5922678A (en) 1996-06-28 1999-07-13 Eli Lilly And Company Methods for treating diabetes
AU7873798A (en) 1996-12-20 1998-07-17 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
IL131796A0 (en) 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
HUP0004169A3 (en) * 1997-10-24 2001-06-28 Lilly Co Eli Insoluble insulin compositions and process for production thereof
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US7193035B2 (en) * 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
JP5697831B2 (ja) 2003-12-03 2015-04-08 ノヴォ ノルディスク アー／エス 単鎖インシュリン
US20100216690A1 (en) 2005-03-18 2010-08-26 Novo Nordisk A/S Pegylated Single-Chain Insulin
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
JP2009530243A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
RU2352113C1 (ru) 2007-06-18 2009-04-20 Владимир Яковлевич Этин Ловушка для эктопаразитов
ITRG20070003A1 (it) * 2007-07-17 2009-01-18 Salvatore Lucifora Metodo e sistema informatico per analizzare le prestazioni e dimensionare una cella underlay/overlay di un sistema di telecomunicazione cellulare
US8575096B2 (en) * 2007-08-13 2013-11-05 Novo Nordisk A/S Rapid acting insulin analogues
KR20100053561A (ko) * 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
PL2254906T3 (pl) * 2008-03-18 2017-04-28 Novo Nordisk A/S Stabilizowane względem proteaz, acylowane analogi insuliny
EP2262539B1 (en) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin albumin conjugates
US20120184487A1 (en) 2009-06-30 2012-07-19 Novo Nordisk A/S Insulin derivatives
CN102665676B (zh) 2009-11-02 2015-04-01 诺沃-诺迪斯克有限公司 非共价结合的白蛋白和酰化胰岛素的药物溶液
WO2011161124A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin analogues containing additional disulfide bonds
JP2013541500A (ja) 2010-07-28 2013-11-14 スマートセルズ・インコーポレイテツド 組換えレクチン、結合部位修飾レクチンおよびそれらの用途
US20140315797A1 (en) 2010-10-15 2014-10-23 Peter Madsen Novel N-Terminally Modified Insulin Derivatives
EP2720711A1 (en) 2011-06-15 2014-04-23 Novo Nordisk A/S Multi substituted insulins
KR20150021011A (ko) 2011-10-27 2015-02-27 케이스 웨스턴 리저브 유니버시티 초고도 농축된, 속효성 인슐린 유사체 제형
WO2013086927A1 (zh) 2011-12-15 2013-06-20 上海恒瑞医药有限公司 人胰岛素类似物及其酰化衍生物
AU2014241743B2 (en) 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
EP3052134B1 (en) 2013-10-04 2021-05-05 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
AU2016311283B2 (en) 2015-08-25 2020-10-08 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN105440125B (zh) 2015-11-25 2019-09-24 华润昂德生物药业有限公司 地特胰岛素或其类似物的制备方法
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
EP4073097A1 (en) 2019-12-11 2022-10-19 Novo Nordisk A/S Novel insulin analogues and uses thereof

Also Published As

Publication number Publication date
KR20180038049A (ko) 2018-04-13
CN108026157B (zh) 2022-11-25
JP2018531900A (ja) 2018-11-01
ES2908373T3 (es) 2022-04-28
US11352406B2 (en) 2022-06-07
CN108026157A (zh) 2018-05-11
IL257173A (en) 2018-06-28
RU2018107727A3 (es) 2019-11-28
RU2018107727A (ru) 2019-10-01
AU2016311283A1 (en) 2018-02-15
AR106364A1 (es) 2018-01-10
CA2996455A1 (en) 2017-03-02
TW201717998A (zh) 2017-06-01
EP3341403A1 (en) 2018-07-04
EP3341403B1 (en) 2022-01-05
US20180305431A1 (en) 2018-10-25
AU2016311283B2 (en) 2020-10-08
WO2017032798A1 (en) 2017-03-02
JP2021177779A (ja) 2021-11-18
BR112018002416A2 (pt) 2018-09-18

Similar Documents

Publication Publication Date Title
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
MX2016010899A (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
MX346494B (es) Compuestos novedosos como inhibidores de diacilglicerol aciltransferasa.
PH12016502352A1 (en) Pharmaceutical composition
PH12019502655A1 (en) Acylated insulin compound
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2023000398A (es) Analogos de insulina novedosos y usos de estos.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
UA115307C2 (uk) Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
SG11201806628UA (en) New bi-aromatic propynyl compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
MX2016001357A (es) Compuestos de ciclobutilo 1,2-disustituidos.